Australian biotech market watch 14/10/09
Wednesday, 14 October, 2009
The All Ordinaries has continued its lift itself out of the dip in early October on the back of positive news about the Australian economy. Today it opened up from yesterday but has thence remained fairly flat at 4,807 as of 11.30am.
Ramsay Health Care (ASX:RHC), which operates over 40 hospitals in the UK, rose over 1% following news of a new service, Premium Care, meant to offer private patients a greater level of service to public patients. It's up 10c to $10.60.
Pain relief pharma company, QRxPharma (ASX:QRX), is up 2.3% to $1.11 on the back of an announcement yesterday of a contractual agreement with US manufacturer, Patheon.
Biota Holdings (ASX:BTA), which receives royalties for anti-viral Relenza, jumped over 4% to $3.23, continuing a month of steady gains.
Liver cancer specialists, Sirtex (ASX:SRX) saw a jump of 3.3% in morning trading to $5.29.
Of the Big Three, Cochlear (ASX:COH) is level at $65.56 after some wobbles earlier in the week, ResMed (ASX:RMD) lost some of its gains from the last week, down today 8c to $5.27 and CSL (ASX:CSL) lifted by 2% to $32.35 after announcing it expected full year profits to be around the $1 billion mark, as expected.
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
